7,764 Shares in Ionis Pharmaceuticals, Inc. $IONS Acquired by Stratos Wealth Partners LTD.

Stratos Wealth Partners LTD. bought a new stake in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 7,764 shares of the company’s stock, valued at approximately $508,000.

A number of other hedge funds and other institutional investors have also bought and sold shares of IONS. Goldman Sachs Group Inc. raised its position in shares of Ionis Pharmaceuticals by 72.5% during the 1st quarter. Goldman Sachs Group Inc. now owns 652,518 shares of the company’s stock valued at $19,686,000 after buying an additional 274,310 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its stake in Ionis Pharmaceuticals by 6.4% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 659,435 shares of the company’s stock valued at $19,895,000 after acquiring an additional 39,794 shares during the last quarter. Focus Partners Wealth raised its position in Ionis Pharmaceuticals by 30.1% during the first quarter. Focus Partners Wealth now owns 9,832 shares of the company’s stock valued at $297,000 after purchasing an additional 2,277 shares in the last quarter. Vanguard Personalized Indexing Management LLC raised its position in Ionis Pharmaceuticals by 17.1% during the second quarter. Vanguard Personalized Indexing Management LLC now owns 12,072 shares of the company’s stock valued at $477,000 after purchasing an additional 1,759 shares in the last quarter. Finally, Y Intercept Hong Kong Ltd bought a new stake in Ionis Pharmaceuticals during the second quarter worth about $1,488,000. Hedge funds and other institutional investors own 93.86% of the company’s stock.

Ionis Pharmaceuticals Trading Up 1.1%

NASDAQ:IONS opened at $82.22 on Thursday. The firm has a market capitalization of $13.32 billion, a P/E ratio of -48.65 and a beta of 0.29. The company has a quick ratio of 2.78, a current ratio of 2.79 and a debt-to-equity ratio of 0.96. The company has a fifty day moving average of $80.80 and a 200 day moving average of $70.11. Ionis Pharmaceuticals, Inc. has a 52 week low of $23.95 and a 52 week high of $86.74.

Insider Buying and Selling

In other news, EVP Eric Swayze sold 15,642 shares of the business’s stock in a transaction that occurred on Friday, February 13th. The stock was sold at an average price of $81.76, for a total transaction of $1,278,889.92. Following the transaction, the executive vice president directly owned 32,105 shares of the company’s stock, valued at approximately $2,624,904.80. The trade was a 32.76% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director B Lynne Parshall sold 5,000 shares of the company’s stock in a transaction that occurred on Wednesday, February 11th. The shares were sold at an average price of $82.72, for a total value of $413,600.00. Following the transaction, the director owned 56,344 shares of the company’s stock, valued at approximately $4,660,775.68. This represents a 8.15% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 481,356 shares of company stock valued at $38,987,621 over the last ninety days. Corporate insiders own 2.60% of the company’s stock.

Analyst Ratings Changes

IONS has been the topic of several recent research reports. TD Cowen reiterated a “buy” rating on shares of Ionis Pharmaceuticals in a research report on Wednesday, December 3rd. Needham & Company LLC increased their price target on shares of Ionis Pharmaceuticals from $78.00 to $90.00 and gave the company a “buy” rating in a research report on Thursday, October 30th. Piper Sandler lifted their price target on shares of Ionis Pharmaceuticals from $77.00 to $87.00 and gave the stock an “overweight” rating in a research note on Friday, February 6th. Royal Bank Of Canada upped their price objective on shares of Ionis Pharmaceuticals from $82.00 to $95.00 and gave the company an “outperform” rating in a research note on Wednesday, December 17th. Finally, Bank of America increased their target price on shares of Ionis Pharmaceuticals from $86.00 to $97.00 and gave the company a “buy” rating in a report on Tuesday, December 9th. One analyst has rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $86.95.

About Ionis Pharmaceuticals

Ionis Pharmaceuticals, Inc is a biotechnology company focused on the discovery and development of RNA-targeted therapies designed to modulate gene expression. The company’s proprietary antisense oligonucleotide (ASO) technology enables the selective binding of short synthetic strands of nucleic acids to messenger RNA (mRNA), thereby inhibiting or altering the production of disease-causing proteins. Ionis’ pipeline spans a range of therapeutic areas, including neurological disorders, cardiovascular conditions, metabolic diseases and rare genetic disorders.

Since its founding in 1989 by Dr.